| 1 -0.13 (-11.5%) | 07-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.33 |
1-year : | 1.49 |
| Resists | First : | 1.13 |
Second : | 1.27 |
| Pivot price | 1  |
|||
| Supports | First : | 0.91 |
Second : | 0.75 |
| MAs | MA(5) : | 1.04 |
MA(20) : | 0.99 |
| MA(100) : | 1.13 |
MA(250) : | 1.3 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 59.3 |
D(3) : | 69.8 |
| RSI | RSI(14): 49.3 |
|||
| 52-week | High : | 3.01 | Low : | 0.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ITRM ] has closed above bottom band by 49.5%. Bollinger Bands are 11.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.13 - 1.14 | 1.14 - 1.14 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 0.99 - 1 | 1 - 1.01 |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Wed, 02 Jul 2025
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Wed, 02 Jul 2025
Iterum Therapeutics Strengthens Leadership Team: New CCO to Drive Next-Gen Antibiotics Commercialization - Stock Titan
Sun, 29 Jun 2025
Certain Options of Iterum Therapeutics plc are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Wed, 25 Jun 2025
Iterum Therapeutics (ITRM) Releases Positive Phase 3 Trial Resul - GuruFocus
Mon, 16 Jun 2025
Transcript : Iterum Therapeutics plc - Special Call - MarketScreener
Wed, 11 Jun 2025
Iterum Therapeutics Inks Partnership With EVERSANA For Commercialization Of ORLYNVAH In US - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 6.4 (%) |
| Shares Short | 1,170 (K) |
| Shares Short P.Month | 1,290 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.08 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.02 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -1.07 |
| PEG Ratio | 0 |
| Price to Book value | -14.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|